Home › Entities › clinical_trial › Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant

clinical trial
MedicalStudy clinical_trial Q93328935
Press Enter · cited answer in seconds

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant

Summary

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant is a clinical trial[1].

Key Facts

  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant is in the country of Australia[2].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's instance of is recorded as clinical trial[3].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's start time is recorded as +2020-05-15T00:00:00Z[4].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's end time is recorded as +2020-12-31T00:00:00Z[5].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's main subject is recorded as NVX-CoV2373[6].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's number of participants is recorded as {'unit': '1', 'amount': '+131'}[7].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's title is recorded as A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects[8].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[9].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's ClinicalTrials.gov ID is recorded as NCT04368988[10].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+59'}[11].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's research intervention is recorded as NVX-CoV2373[12].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's clinical trial phase is recorded as phase I clinical trial[13].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's research subject recruitment status is recorded as recruiting[14].
  • Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant's study type is recorded as interventional study[15].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . covid-19tracker.milkeninstitute.org. Retrieved . covid-19tracker.milkeninstitute.org. Provenance: wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . covid-19tracker.milkeninstitute.org. Retrieved . covid-19tracker.milkeninstitute.org. Provenance: wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant. Retrieved May 3, 2026, from https://4ort.xyz/entity/evaluation-of-the-safety-and-immunogenicity-of-a-sars-cov-2-rs-covid-19-nanoparticle-vaccine-with-without-matrix-m-adjuvant
MLA “Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/evaluation-of-the-safety-and-immunogenicity-of-a-sars-cov-2-rs-covid-19-nanoparticle-vaccine-with-without-matrix-m-adjuvant.
BibTeX @misc{4ortxyz_evaluation-of-the-safety-and-immunogenicity-of-a-sars-cov-2-rs-covid-19-nanoparticle-vaccine-with-without-matrix-m-adjuvant_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant}}, year = {2026}, url = {https://4ort.xyz/entity/evaluation-of-the-safety-and-immunogenicity-of-a-sars-cov-2-rs-covid-19-nanoparticle-vaccine-with-without-matrix-m-adjuvant}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant — https://4ort.xyz/entity/evaluation-of-the-safety-and-immunogenicity-of-a-sars-cov-2-rs-covid-19-nanoparticle-vaccine-with-without-matrix-m-adjuvant (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/evaluation-of-the-safety-and-immunogenicity-of-a-sars-cov-2-rs-covid-19-nanoparticle-vaccine-with-without-matrix-m-adjuvant · Last refreshed: